Aktis Oncology Reports Q3 2026 Results, $492.9M Cash Position

Aktis Oncology reported third-quarter 2026 collaboration revenue of $3.9 million and a net loss of $29.9 million. Cash, cash equivalents and marketable securities totaled $492.9 million at September 30, 2026, which the company expects to fund its operating plan into 2029. The company also initiated…